The video illustrates that two bundles of chelators with radioactive nuclei (effector moiety) are conjugated to an antibody molecule specific for a tumor-associated surface antigen (targeting moiety) in a site-specific fashion. The resulting antibody radionuclide conjugate (ARC) with a drug to antibody ratio (DAR) of 6 is used for administration to a patient bearing tumor expressing the specific antigen. The ARC binds to the tumor cells, and the emission of beta particles from the nuclei causes the lysis of the tumor cells and adjacent cells.